What's in MedImmune LLC's pipeline?

MedImmune LLC has 84 drugs in our index: 11 marketed, 0 filed, 16 in Phase 3, 19 in Phase 2, 38 in Phase 1.

Which companies overlap with MedImmune LLC's portfolio?

Top competitors by shared drug class: GlaxoSmithKline, Sanofi Pasteur, a Sanofi Company, Novartis, National Cancer Institute (NCI), Green Cross Corporation.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/medimmune-llc.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-06-10 · How we verify

MedImmune LLC — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

MedImmune LLC pipeline: 11 marketed, 0 filed, 16 Phase 3, 19 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

11 marketed 0 filed 16 Phase 3 19 Phase 2 38 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
ICE	ICE	marketed	Caspase inhibitor	Caspase-1 (ICE)	Immunology
FluMist trivalent (2015-2016)	FluMist trivalent (2015-2016)	marketed	Live attenuated influenza vaccine		Immunology
Liquid Palivizumab	Liquid Palivizumab	marketed	Monoclonal antibody (RSV F protein inhibitor)	RSV F (fusion) protein	Immunology / Infectious Disease
Trivalent Influenza Vaccine	Trivalent Influenza Vaccine	marketed	Inactivated influenza vaccine		Immunology
Monovalent influenza virus vaccine	Monovalent influenza virus vaccine	marketed
Bivalent influenza vaccine	Bivalent influenza vaccine	marketed
Monovalent Influenza Vaccine	Monovalent Influenza Vaccine	marketed
Monovalent Frozen FluMist®	Monovalent Frozen FluMist®	marketed
Lyophilized Palivizumab	Lyophilized Palivizumab	marketed
FluMist Quadrivalent (2017-2018)	FluMist Quadrivalent (2017-2018)	marketed	Live attenuated influenza vaccine (LAIV)	Influenza virus	Immunology
Trivalent Influenza Virus Vaccine	Trivalent Influenza Virus Vaccine	marketed
CAIV-T, Liquid	CAIV-T, Liquid	phase 3	Live attenuated influenza vaccine		Immunology

Therapeutic area mix

Immunology / Infectious Disease · 10
Immunology · 9
Respiratory · 2
Infectious Disease · 1
Metabolic · 1
Oncology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

GlaxoSmithKline · 5 shared drug classes
Sanofi Pasteur, a Sanofi Company · 3 shared drug classes
Novartis · 3 shared drug classes
National Cancer Institute (NCI) · 2 shared drug classes
Green Cross Corporation · 2 shared drug classes
ModernaTX, Inc. · 2 shared drug classes
Centers for Disease Control and Prevention · 2 shared drug classes
Assistance Publique - Hôpitaux de Paris · 2 shared drug classes

Subscribe to ongoing alerts

Every new pipeline event for MedImmune LLC:

Cite this brief

Drug Landscape (2026). MedImmune LLC — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/medimmune-llc. Accessed 2026-06-10.